COVID-19 Vaccines Global Market Outlook to 2026: Trends & Analysis, Epidemiology, Unmet Needs & Opportunities, Therapeutic Landscape, Pipeline Assessment, Clinical Trial Strategies
23 janv. 2024 16h03 HE
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines Market Size, Trends and Analysis by Disease Overview, Epidemiology, Unmet Needs and Opportunities, Therapeutic Landscape, Pipeline...
Author and Health Equity Leader Daniel E. Dawes, J.D., to Keynote Inaugural Health Summit
18 janv. 2024 07h00 HE
|
The Immunization Partnership
HOUSTON, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The Immunization Partnership (TIP), a statewide nonprofit committed to a healthy Texas, announced Daniel E. Dawes, J.D., as the keynote speaker for its...
2023 U.S. Vaccine Market Report Unveils Growth Trends and Forecasts Through 2030: COVID-19 Vaccines, Adult Vaccination Rates, Influenza Vaccine Production
18 janv. 2024 05h58 HE
|
Research and Markets
Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The "2023 U.S. Vaccine Market Report" report has been added to ResearchAndMarkets.com's offering. In a comprehensive analysis of the U.S. vaccine market,...
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc....
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
16 janv. 2024 06h00 HE
|
Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Antivenom Global Market Report 2023
04 janv. 2024 16h38 HE
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Antivenom Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.Antivenom, also known as antivenin, is an antibody...
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
04 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation
20 déc. 2023 06h10 HE
|
Intravacc B.V.
Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.
Quadrivalent Virus-Like Particle (VLP) Vaccine Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032
14 déc. 2023 10h03 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...